多西他赛为主方案治疗非小细胞肺癌35例分析  

Docetaxel combination therapy for treatment of non-small cell lung cancer:Report of 35 cases

作　　者：杨玲[1] 

机构地区：[1]安徽省蚌埠市第三人民医院呼吸内科,233000

出　　处：《蚌埠医学院学报》2008年第3期301-302,共2页Journal of Bengbu Medical College

摘　　要：目的:观察以多西他赛为主方案治疗非小细胞肺癌的疗效。方法:35例非小细胞肺癌用多西他赛100 mg d1静脉滴注,分别配伍顺铂100 mg或奥沙利铂200 mg,静脉滴注d1,3周为1周期,4周期后按WHO标准评价疗效。结果:35例中CR1例,PR 21例,NC 10例,PD 3例,总有效率(CR+PR)62.86%。主要毒副作用是骨髓抑制、消化道反应和脱发。结论:多西他赛为主方案是目前治疗非小细胞肺癌的安全可靠方案。Objective ：To observe the efficacy and side effect of docetaxel combination therapy on advanced non-small-cell lung cancer （NSCLC）. Methods：Thirty-five patients with NSCLC were treated by docetaxel 100 mg intravenous d1 , combined with cisplatin 100 mg or oxaliplatin intravenous 200 mg d1 ,respectively. The therapy was repeated every 3 weeks. After 4 cycles the effects and side effects were evaluated by WHO crteria. Results ：CR was achieved in 1 , PR in 21, NC in 10 and PD in 3. The overall response rate （CR ＋ PR） was 62. 86%. The major toxicities were, nauser/vomiting, neutropenia and alopecie. Conclusions： Docetaxel-based combination chemotherapy is safe and effective for treatment of advanced NSCLC.

关 键 词：肺肿瘤 癌 非小细胞肺 肿瘤/药物疗法 多西他赛 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]